Overview
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Background
Physiologic methyl radical donor involved in enzymatic transmethylation reactions and present in all living organisms. It possesses anti-inflammatory activity and has been used in treatment of chronic liver disease. (From Merck, 11th ed)
Indication
S-Adenosylmethionine (SAMe) is used as a drug in Europe for the treatment of depression, liver disorders, fibromyalgia, and osteoarthritis. It has also been introduced into the United States market as a dietary supplement for the support of bone and joint health, as well as mood and emotional well being.
Associated Conditions
- Fatigue
- Intrahepatic Cholestasis
- Major Depressive Disorder (MDD)
Research Report
Ademetionine Report
Name: Ademetionine Name (English): Ademetionine DrugBank ID: DB00118 Type: Small Molecule CAS Number: 29908-03-0
Uses: Ademetionine is used to treat various conditions, including:
- Liver diseases (e.g., cholestatic liver diseases, alcoholic fatty liver disease, non-alcoholic fatty liver disease, liver disease during pregnancy, liver conditions with reduced bile formation).
- Depression.
- Osteoarthritis (to reduce pain and swelling in the joints).
- Biliary cholangitis (an autoimmune disease of the liver).
- Excess cholesterol in bile and biliary and liver diseases caused by cystic fibrosis.
- Fibromyalgia symptoms.
- Nerve problems in people with AIDS.
- Sexual dysfunction in men with depression.
Mechanism of Action: Ademetionine (S-adenosylmethionine or SAMe) is a naturally occurring compound involved in several crucial biological processes:
- Methylation: It acts as a methyl donor in the transfer of a methyl group to other molecules like DNA, proteins, and lipids, which is essential for gene expression, protein function, and lipid metabolism.
- Trans-sulfuration: It participates in the synthesis of cysteine and glutathione, a vital antioxidant that protects liver cells from toxins and oxidative stress.
- Aminopropylation: It is a precursor in the synthesis of polyamines, which are involved in cellular growth and repair. In liver disease, ademetionine helps maintain glutathione levels, minimizing liver damage and preventing the accumulation of lipids associated with cirrhosis. In depression, it affects neurotransmitters like serotonin, which regulate mood. In osteoarthritis, it may stimulate cartilage production and reduce inflammation.
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2025/04/10 | Not Applicable | Recruiting | General Hospital of Shenyang Military Region | ||
2023/11/18 | Phase 3 | Recruiting | |||
2020/11/10 | Phase 1 | Completed | |||
2020/02/05 | Phase 4 | Active, not recruiting | Oslo University Hospital | ||
2020/01/31 | Phase 2 | Recruiting | |||
2016/09/21 | Phase 4 | Terminated | University of Chile | ||
2015/12/31 | Not Applicable | Completed | |||
2014/09/04 | Not Applicable | Completed | |||
2014/07/25 | Phase 3 | Completed | |||
2013/12/02 | Phase 4 | UNKNOWN | Zhejiang Hisun Pharmaceutical Co. Ltd. |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Ademetionine 1,4-Butanedisulfonate Enteric Coated Tablets | 国药准字H20249303 | 化学药品 | 片剂 | 11/5/2024 | |
Ademetionine 1,4-Butanedisulfonate Enteric Coated Tablets | abbott laboratories (m) sdn. bhd | 国药准字HJ20150629 | 化学药品 | 片剂 | 7/24/2020 |
Ademetionine 1,4-Butanedisulfonate Enteric Coated Tablets | 国药准字H20133197 | 化学药品 | 片剂 | 1/18/2023 | |
Ademetionine 1,4 - Butanedisulfonate for injection | 国药准字H20244834 | 化学药品 | 注射剂 | 9/10/2024 | |
Ademetionine 1,4 - Butanedisulfonate for injection | 国药准字H20213159 | 化学药品 | 注射剂 | 3/9/2021 | |
Ademetionine 1,4 - Butanedisulfonate for injection | 国药准字H20249623 | 化学药品 | 注射剂 | 12/1/2024 | |
Ademetionine 1,4 - Butanedisulfonate for injection | 国药准字H20249503 | 化学药品 | 注射剂 | 12/1/2024 | |
Ademetionine 1,4 - Butanedisulfonate for injection | abbott laboratories de mexico,s.a. de c.v. | 国药准字HJ20171084 | 化学药品 | 注射剂 | 9/18/2021 |
Ademetionine 1,4 - Butanedisulfonate for injection | 国药准字H20103110 | 化学药品 | 注射剂 | 9/3/2024 | |
Ademetionine 1,4 - Butanedisulfonate for injection | abbott laboratories de mexico,s.a. de c.v. | 国药准字HJ20171069 | 化学药品 | 注射剂 | 9/18/2021 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |